ArticleThe Journal of clinical investigation2012
IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
139 citing papers in PubMed, 1 synthesis or guideline pooled it, 200 citations in OpenAlex.
- Association of the IL-13 polymorphisms rs1800925 and rs20541 with chronic obstructive pulmonary disease risk: An updated meta-analysis.Medicine · 2017Pooled it
- A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule.The European respiratory journal · 2025Trial
- Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.Respiratory research · 2020Trial
- p38γ and p38δ MAP kinases in inflammation.Biochemical Society transactions · 2026Review
- Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma.Pulmonary therapy · 2026Review
- Nasal Airway Transcriptome Reflects Selected Asthma-Associated Gene Signatures in the Lower Airways.Allergy · 2026Article
- Obesity-related palmitic acid exacerbates IL-13-induced mucus phenotype in 16HBE airway epithelial cells via AMPK suppression.Translational pediatrics · 2026Article
- Cell-Type Deconvolution of Equine BALF RNA-Seq: A Critical Comparison with Matched Single-Cell Data.Genes · 2026Article
- Floridoside as a Hinge-Targeted Inhibitor of MAPK13: Atomistic Insights from Molecular Dynamics Simulations.Marine drugs · 2026Article
- Targeting of kinases to treat neurodegenerative diseases.Pharmacological reviews · 2026Review
- Cadherin-11 serves as a novel receptor for Fusobacterium nucleatum adhesin FadA to exacerbate pulmonary inflammation.PLoS pathogens · 2026Article
- Review
- Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogens.Nature nanotechnology · 2026Article
- Mucus plugs-associated gene expression identifies pathophysiology shared with chronic bronchitis.American journal of respiratory and critical care medicine · 2026Article
- Comparison of Tylophora indica with Tylophora pauciflora coupled with network pharmacology of phenanthroindolizidine alkaloids sheds light on its antiallergic potential.Molecular biology reports · 2026Article
- Single Cell Transcriptomic Atlas Reveals Cellular Heterogeneity and Molecular Mechanisms in Pediatric Airway Hyperresponsiveness Epithelium.International journal of genomics · 2026Article
- MTOR signaling regulates the development of airway mucous cell metaplasia associated with severe asthma.JCI insight · 2025Article
- Integrating Bulk RNA and Single-Cell Sequencing Data Reveals Genes Related to Energy Metabolism and Efferocytosis in Lumbar Disc Herniation.Biomedicines · 2025Article
- Decreased Sputum Type-2 Gene Expression in COPD Current Smokers.International journal of chronic obstructive pulmonary disease · 2025Article
- Exogenous acetate mitigates later enhanced allergic airway inflammation in a menopausal mouse model.Frontiers in cellular and infection microbiology · 2025Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise molecular mechanisms for pathogenic mucus production are largely undetermined. Accordingly, there are no specific and effective anti-mucus therapeutics. Here, we define a signaling pathway from chloride channel calcium-activated 1 (CLCA1) to MAPK13 that is responsible for IL-13-driven mucus production in human airway epithelial cells. The same pathway was also highly activated in the lungs of humans with excess mucus production due to COPD. We further validated the pathway by using structure-based drug design to develop a series of novel MAPK13 inhibitors with nanomolar potency that effectively reduced mucus production in human airway epithelial cells. These results uncover and validate a new pathway for regulating mucus production as well as a corresponding therapeutic approach to mucus overproduction in inflammatory airway diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.